Vol. 4, No. 5 May, 2000

 

Number

Subject

040501

Ranbaxy's Ambitious thrust into Europe

040502

Flavopiridol Has Indian Origin

040503

Kopran to Market Perfume Range

040504

Torrent Launches Diabetes Drug

040505

Government Clears Nicholas' ADR Issue

040506

Tax Holiday for Research Has Conditions

040507

Zydus Cadila to Take-over Recon's Formulation Business

040508

JK Pharmachem in Financial Restructuring Exercise

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

New Products, Processes & Services

040501 Ranbaxy’s Ambitious thrust into Europe

Ranbaxy is initiating marketing thrust in the European region targetted at 12 European countries comprising: Belgium, Spain, Finland, Sweden, Denmark, Norway, Portugal, Austria, Hungary, Czech Republic and the Slovak Republic. It is in the process of finalising supply contracts for these countries. In Sweden, Finland and Norway its products will be marketed under its own name while in France, it will market to other companies who will sell it under its own name. In UK, Germany and Poland it has its own subsidiaries. The products manufactured in India, will be shipped to its Ireland plant from where it will be distributed across Europe. The company has been working on this strategy for the past 15 years.

040502 Flavopiridol Has Indian Origin

A drug to battle cancer which has its origin in the Hoechst Research Centre at Mulund, Mumbai, reportedly has a 30-40 per cent chance of coming into the market and is useful against multiple forms of cancer, as big as Taxotere. The product has been developed and is in the middle of clinical trials. Hoechst has subsequently merged with Rhone-Poulenc to create Aventis. The drug is reportedly the pride of Aventis’ research and development team. The Hoechst Research Centre at Mulund is where Indian researchers first isolated flavopiridol from a plant source.

040503 Kopran to Market Perfume Range

Kopran Pharma is marketing a range of perfumes called ‘American Dreams.’ It has also entered the gastro-intestinal segment with the digestive table, ‘Yum Tum.’ This will be in Hajmola’s market segment with a market potential of Rs 160 crore. The company has drawn up an ambitious advertising programme for these products.

040504 Torrent Launches Diabetes Drug

A new product Eurepa (repaglinide) suited to Indian type-II diabetic patients has been launched by Torrent Pharmaceuticals. Reportedly the company claims that Eurepa fulfils the long-felt need of endocrinologist, diabetologists, cardiologists, physicians and nephrologist to maintain their patients’ blood sugar levels.

Government Policies

040505 Government Clears Nicholas’ ADR Issue

Among the investment proposals cleared by the government is Nicholas Piramal’s Rs 430-crore ADR proposal. This issue will fund its research and development activities.

040506 Tax Holiday for Research Has Conditions

The finance minister’s move to give a tax holiday to pharmaceutical research and development firms was widely welcomed by the pharmaceutical industry. The condition is that the company will have to be registered in India and will have to complete all necessary formalities between April 1, 2000 and March 31, 2003. Also, their main line of business must be scientific and industrial research and development. Also this tax holiday will be available for a fixed period till March 31, 2013. The WTO regime does not approve of tax holidays but recognises research and development tax exemptions. Since the country will be implementing WTO guidelines this tax holiday will be discontinued after 2013.

 

 

 

Mergers, Acquisitions And Restructuring

040507 Zydus Cadila to Take-over Recon’s Formulation Business

The Rs 478-crore, Zydus Cadila, based in Ahmedabad is in the process of acquiring the formulations business of the Rs 54-crore Recon, based in Bangalore. All the formulation brands of Recon will be transferred to a new joint-venture which will be a subsidiary of Zydus. The acquisition will also include Recon’s export business. The new joint-venture will be called Recon Healthcare with Recon continuing to manufacture formulations at its facilities for the new company. Zydus will hold 90 per cent equity in the company with rest being held by the shareholders of Recon. The acquisition will strengthen Zydus’ formulations business in the analgesic, anti-inflammatory and cardio-vascular segments. Recon’s leading brands are Atenex and Vasonit in the cardio-vascular segment and Inac and Remulide in the pain management segment. They also have the haematinic Ziferrin TR, a sustained release preparation and LANS-OD an anti-ulcerant.

Other News

040508 JK Pharmachem in Financial Restructuring Exercise

JK Pharmachem, the Penicillin-G manufacturer is on a major financial restructuring exercise, which will help it to reduce its debt by 7 per cent. It will convert 25 per cent of its total Rs 90-crore debt into equity. This will enable the company to save Rs 11 crore in costs and is likely help it to post a profit in the next quarter. The approval for the restructuring has been received from financial institutions including UTI and Tidco. UTI and Tidco account for 90 per cent of the total debt. The parent JK Group will also enhance its stake with this exercise.

The company is also undertaking a restructuring in operations. This includes introducing new technology for formulations, new fermentation-based products and stopping power purchases from state electricity boards. It has started manufacturing its own power.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RESULTS INNOVATOR – THE BENCHMARKING TOOL

Comp.

Acc. Year

Latest Annual

Result

Quarter 1

Quarter 2

Half Year

Quarter 3

Quarter 4

   

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Lupin Labs.

Apr.99

Mar.00

715.7

25.30

190

12.86

189.3

12.8

379.4

25.66

-

-

-

-

% chng.

-

-

-

+2.3

+30

3

42

3

35

-

-

-

-

Orchid

Chem.

Apr.99

Mar.00

359.5

38.59

-

-

-

-

175.3

19.21

-

-

-

-

% chng.

-

+7.5

+8.5

-

-

-

-

+33

+9

-

-

-

-

Pfizer

Dec.99

Nov.99

-

-

-

-

-

-

-

-

76.97

9.87

-

-

% chng.

-

-

-

-

-

-

-

-

-

+26

+8

-

-

Abbott Labs.

Apr.99

Mar.00

-

-

-

-

58.24

2.88

-

-

28.04

1.19

-

-

% chng.

-

-

-

-

-

+8

+73

-

-

+18

+85

-

-

Pun. Chem.

Apr.99

Mar.00

-

-

-

-

19.18

0.09

37.67

.19

-

-

-

-

% chng.

-

-

-

-

-

-13

-91

-5

-90

-

-

-

-

Unichem Labs.

Apr.99

Mar.00

-

-

-

-

56.38

4.88

-

-

-

-

-

-

% chng.

-

-

-

-

-

+8

+35

-

-

-

-

-

-

Ranbaxy Labs.

Apr.99

Mar.00

-

-

-

-

409.7

77.9

-

-

-

-

-

-

% chng.

-

-

-

-

-

-1.6

+54

-

-

-

-

-

-

Glaxo

Jan.99

Dec.00

-

-

-

-

-

-

-

-

248

16

-

-

% chng.

-

-

-

-

-

-

-

-

-

+32

-26

-

-

Shashun

Chem.

Apr.99

Mar.00

165.7

7.50

-

-

42.89

4.55

-

-

48.60

6.38

-

-

% chng.

-

-

-

-

-

-1

+82

-

-

+18

+234

-

-

Suven Pharma.

Apr. 99

Mar.00

30.98

2.50

-

-

9.73

1.02

-

-

9.45

1.14

-

-

% chng.

-

-

-

-

-

+13

+54

-

-

+9

+65

-

-

Neuland Labs.

Apr.99

Mar.00

65.97

2.1

-

-

18.51

n.a.

-

-

19.89

.43

-

-

% chng.

-

-

-

-

-

+8

n.a.

-

-

+29

+38

-

-

Cipla

Apr.99

Mar.00

617.2

114.9

-

-

199.7

35.75

-

-

187.1

34.82

-

-

% chng.

-

-

-

-

-

+23

+14

-

-

+14

+5

-

-

Panacea

Biotec

Apr.99

Mar.00

-

-

-

-

-

3.66

57.95

5.70

85.40

11.94

-

-

% chng.

-

-

-

-

-

-

+35

+39

+36

+107

+234

-

-

Torrent

Pharma.

Apr.99

Mar.00

-

-

-

-

101.1

18.80

-

-

161.2

22.9

-

-

% chng.

-

-

-

-

-

+13

+75

-

-

+103

+229

-

-

Knoll

Pharma

Jan.99

Dec.99

-

-

-

-

-

-

-

-

77.5

40.6

-

-

% chng.

-

-

-

-

-

-

-

-

-

+9

+286

-

-

Parke

Davis

Apr.99

Mar.00

200.3

16.61

-

-

52.93

4.31

101.0

8.14

51.08

6.78

-

-

% chng.

-

+11

+139

-

-

+6

+85

+0.2

+42

+7

+276

-

-

Makers

Labs

Apr.99

Mar.00

23.95

0.80

-

-

8.93

0.3

17.05

0.64

-

-

-

-

% chng.

-

-

-

-

-

+20

+11

+17

+42

-

-

-

-

Sun

Pharma

Apr.99

Mar.00

335.6

59.04

-

-

112.8

22.79

215.8

42.8

112.3

22.89

-

-

% chng.

-

-

-

-

-

+35

+53

+41

+60

+24

+48

-

-

Bal

Pharma

Apr.99

Mar.00

24.89

0.62

-

-

8.26

0.44

14.44

0.57

-

-

-

-

% chng.

-

-

-

-

-

+22

+158

+17

+72

-

-

-

-

Vorin

Labs

Apr.99

Mar.00

72.85

2.35

-

-

15.56

0.19

35.1

12.5

-

-

-

-

% chng.

-

-

-

-

-

-43

-76

-20

-42

-

-

-

-

Ipca

Labs

Apr.99

Mar.00

335.4

21.4

-

-

95.22

8.09

171.8

15.9

96.58

6.76

-

-

% chng.

-

-

-

-

-

+1

+105

+0.5

+48

+20

+60

-

-

Dr. Reddy’s

Apr.99

Mar.00

-

-

-

-

113.5

-

239.9

-

121

22

-

-

% chng.

-

-

-

-

-

+4

-

+7

-

+34

+103

-

-

Comp.

Acc. Year

Latest Annual

Result

Quarter 1

Quarter 2

Half Year

Quarter 3

Quarter 4

   

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

Sales

(Cr.)

Net

(Cr.)

J B Chem.

Apr.’99

Mar.’00

152.8

14.53

-

-

40.65

4.65

82.78

10.15

43.60

5.54

-

-

% chng.

-

-

-

-

-

+3

+75

+5

+30

+27

+121

-

-

Dabur

India

Apr.’99

Mar.’00

914.7

51.60

-

-

261.6

18.91

495.1

440.1

286.4

15.41

-

-

% chng.

-

-

-

-

-

+6

-21

+12

+91

+10

+15

-

-

Morepen

Labs.

Apr.’99

Mar.’00

256.5

34.3

-

-

84.6

12.2

155.5

21.6

84.7

12.4

-

-

% chng.

-

-

-

-

-

+24

+43

+28

+43

+30

+42

-

-

Nich.

Piramal

Apr.’99

Mar.’00

-

-

-

-

124.2

14.12

237.1

25.57

114.6

11.23

-

-

% chng.

-

-

-

-

-

+12

+25

+12

+23

+11

+22

-

-

Wock-

hardt.

Jul.’98

Dec.’99

-

-

209.0

34.0

-

-

-

-

-

-

-

-

% chng.

-

-

-

+36

+45

-

-

-

-

-

-

-

-

Ind-Swift

Labs

Apr.’99

Mar.’00

42.65

12.3

 

-

15.58

.8

29.85

1.55

16.08

.85

-

-

% chng.

-

-

-

-

-

+54

+220

+58

+288

+76

+205

-

-

Veronica

Labs.

Apr.’99

Mar.’00

7.19

.25

-

-

5.81

.41

11.08

.92

-

-

-

-

% chng.

-

-

-

-

-

-

-

-

-

-

-

-

-

Auro-

bindo

Apr.’99

Mar.’00

550.0

50.14

-

-

174.2

18.61

357.3

37.2

178

19.57

-

-

% chng.

-

-

-

-

-

+20

+63

+44

+85

+31

+35

-

-

Novartis

India

Apr.’99

Mar.’00

-

-

-

-

-

-

424

49

-

-

-

-

% chng.

-

-

-

-

-

-

-

-

-

-

-

-

-

FDC

Apr.’99

Mar.’00

140.2

15.28

-

-

-

-

-

-

28.02

4.86

-

-

% chng.

 

-

-

           

-2

+19

-

-

Glenmark

Apr.’99

Mar.’00

138.0

21.96

-

-

-

-

-

-

30.15

4.90

-

-

% chng.

-

+39

+71

-

-

-

-

-

-

+6

+191

-

-

Aarti

Apr.’99

Mar.’00

132.3

4.05

-

-

-

-

-

-

32.13

1.55

-

-

% chng.

-

-

-

-

-

-

-

-

-

-5

+86

-

-

Duphar

Apr.’99

Mar.’00

64.49

3.82

-

-

-

-

-

-

19.55

2.61

-

-

% chng.

-

-

-

-

-

-

-

-

-

+27

+15

-

-

Kopran

Apr.’99

Mar.’00

203.7

10.30

-

-

-

-

-

-

56.75

4.01

-

-

% chng.

-

-

-

-

-

-

-

-

-

+10

-7

-

-

Siris

Apr.’99

Mar.’00

240.8

10.09

-

-

-

-

-

-

31.94

-20.4

-

-

% chng.

-

-

-

-

-

-

-

-

-

-35

-

-

-

Krebs Bio

Apr.’99

Mar.’00

36.84

11.27

-

-

-

-

-

-

12.23

3.92

-

-

% chng.

-

-

-

-

-

-

-

-

-

+52

+30

-

-

Jenburkt

Apr.’99

Mar.’00

13.93

.25

-

-

-

-

-

-

3.92

.17

-

-

% chng.

-

-

-

-

-

-

-

-

-

+27

+9

-

-

Max India

Jul.’99

Jun.’00

288

176

-

-

41.03

12.29

77.32

22.76

-

-

-

-

% chng.

-

-

-

-

-

+68

+403

+50

+340

-

-

-

-